Valuation : Arvinas, Inc.

Market Cap 607M 523M 492M 449M 843M 57.59B 848M 5.82B 2.27B 29.29B 2.28B 2.23B 97.13B P/E 2026 *
-412x
P/E 2027 * -2.66x
Enterprise Value 156M 135M 127M 115M 217M 14.81B 218M 1.5B 583M 7.53B 586M 573M 24.98B EV / Sales 2026 *
0.53x
EV / Sales 2027 * 4.67x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day+2.96%
1 week-3.33%
Current month+0.87%
1 month+15.57%
3 months+8.16%
6 months-30.07%
Current year-21.75%
1 week 8.96
Extreme 8.9601
9.43
1 month 7.92
Extreme 7.92
9.74
Current year 6.97
Extreme 6.97
14.51
1 year 6.97
Extreme 6.97
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
98.67
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 11/02/2026
Director of Finance/CFO 56 23/06/2024
Chief Tech/Sci/R&D Officer 58 16/06/2024
Director TitleAgeSince
Chairman 66 14/06/2023
Director/Board Member 64 30/06/2018
Chairman 67 11/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/05/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/05/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+2.96%-3.33%+20.05%-66.68% 607M
-0.25%-4.10%+38.38%+92.61% 68.21B
+3.59%+2.27%+51.49%+93.30% 64.25B
+2.06%-1.92%-10.72%+436.70% 26.54B
+2.32%-10.61%+1.95%-16.27% 25.61B
+3.12%+1.48%+32.63%-17.72% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+2.86%+0.30%+52.03%+150.18% 14.1B
+1.37%+5.18%+23.04%+190.97% 12.45B
Average +1.19%-3.86%+43.38%+177.30% 26.37B
Weighted average by Cap. +1.29%-3.22%+42.58%+159.26%

Financials

2026 *2027 *
Net sales 296M 255M 240M 219M 412M 28.1B 414M 2.84B 1.11B 14.29B 1.11B 1.09B 47.4B 64.19M 55.37M 52.09M 47.45M 89.23M 6.09B 89.72M 616M 240M 3.1B 241M 236M 10.28B
Net income -666K -575K -541K -493K -926K -63.24M -931K -6.39M -2.49M -32.17M -2.5M -2.45M -107M -248M -214M -201M -183M -345M -23.52B -346M -2.38B -925M -11.97B -931M -910M -39.68B
Net Debt -451M -389M -366M -333M -627M -42.78B -630M -4.32B -1.68B -21.76B -1.69B -1.66B -72.15B -307M -265M -249M -227M -427M -29.12B -429M -2.94B -1.15B -14.81B -1.15B -1.13B -49.12B
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
01/09/26 US$9.280 +0.87% 491,140
31/08/26 US$9.200 +0.22% 659,720
28/08/26 US$9.180 -0.65% 600,337
27/08/26 US$9.240 -0.86% 527,006
26/08/26 US$9.320 -2.92% 532,586
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
9.280USD
Average target price
13.93USD
Spread / Average Target
+50.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARVN Stock